Bach D, Klein B C, Grabensee B
Department of Nephrology, Heinrich-Heine University Düsseldorf Germany.
Ren Fail. 1997 Jan;19(1):85-98. doi: 10.3109/08860229709026263.
If nontreated or misdiagnosed, acute crescentic glomerulonephritis, clinically defined as rapidly progressive glomerulonephritis (RPGN), may led to end-stage renal failure (ESRD) within a short time. Histologically, it is characterized by accumulation of inflammatory cells in combination with proliferation of epithelial cells in the glomerulus. According to the proposed immunopathogenic classification by Couser (7), predominantly the immunopathogenic type III without immune deposits often represents the renal manifestation of a systemic vasculitic disease, for example, polyarteriitis or Wegener's granulomatosis. Having investigated 75 patients with acute crescentic glomerulonephritis in respect to their long-term results, we conclude that an early histopathologic diagnosis by using an activity and chronicity score system may not only be a predictor for renal prognosis but also be a valid supposition for differentiated immunosuppressive therapy in supplement to the clinical data on renal function. A therapeutic advantage of a plasmapheresis therapy additionally to the immunosuppressive therapy could not be proven.
如果不进行治疗或误诊,临床上定义为快速进展性肾小球肾炎(RPGN)的急性新月体性肾小球肾炎可能在短时间内导致终末期肾衰竭(ESRD)。在组织学上,其特征是炎症细胞积聚并伴有肾小球上皮细胞增殖。根据Couser提出的免疫致病分类法(7),主要是无免疫沉积物的III型免疫致病型通常代表系统性血管炎疾病的肾脏表现,例如,结节性多动脉炎或韦格纳肉芽肿。在对75例急性新月体性肾小球肾炎患者的长期结果进行研究后,我们得出结论,使用活动度和慢性度评分系统进行早期组织病理学诊断不仅可以预测肾脏预后,而且对于在补充肾功能临床数据的基础上进行差异化免疫抑制治疗也是一个有效的假设。血浆置换疗法相对于免疫抑制疗法的治疗优势尚未得到证实。